S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
The single greatest medical breakthrough of all time? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
The single greatest medical breakthrough of all time? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
The single greatest medical breakthrough of all time? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
3 Reasons This Sleeping Giant Is About To Wake Up
The single greatest medical breakthrough of all time? (Ad)
MarketBeat Week in Review – 9/18 - 9/22
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
The single greatest medical breakthrough of all time? (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
The single greatest medical breakthrough of all time? (Ad)
Auto workers still have room to expand their strike against car makers. But they also face risks
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Forecast, Price & News

$14.31
+0.01 (+0.07%)
(As of 09/22/2023 ET)
Compare
Today's Range
$13.89
$14.79
50-Day Range
$13.92
$15.43
52-Week Range
$10.99
$15.86
Volume
81,205 shs
Average Volume
49,643 shs
Market Capitalization
$47.08 billion
P/E Ratio
16.26
Dividend Yield
1.40%
Price Target
N/A

Chugai Pharmaceutical MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
-7.69%
From $2.73 to $2.52 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.43 out of 5 stars


CHGCY stock logo

About Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

CHGCY Price History

CHGCY Stock News Headlines

TOPIX Pharmaceutical (IPHAM.T)
Chugai Pharmaceutical Co. Ltd.
3 Words and a 3,000% Return
In October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>
Here's what to expect from Chugai Pharmaceutical's earnings report
CHGCY Chugai Pharmaceutical Co., Ltd.
3 Words and a 3,000% Return
In October 2013, a scientist wrote 3 words on a piece of paper. They were simple words. A fiveyear-old could say them. But these three words could deliver you a 3,000% return in 2023 >>>
Short Volatility Alert: Chugai Pharm Co
Chugai Pharmaceutical reports Q1 results
Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Chugai Pharmaceutical Co., Ltd. (CHGCY)
Chugai Pharmaceutical Co. Ltd. ADR
See More Headlines
Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

CHGCY Company Calendar

Today
9/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CHGCY
Fax
N/A
Employees
7,664
Year Founded
N/A

Profitability

Net Income
$2.88 billion
Pretax Margin
42.16%

Debt

Sales & Book Value

Annual Sales
$9.65 billion
Cash Flow
$0.95 per share
Book Value
$3.33 per share

Miscellaneous

Outstanding Shares
3,289,980,000
Free Float
N/A
Market Cap
$47.08 billion
Optionable
Not Optionable
Beta
0.63
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Osamu Okuda (Age 60)
    Pres, CEO & Representative Director
    Comp: $1.24M
  • Mr. Toshiaki Itagaki (Age 63)
    Head of Fin. Supervisory Division, CFO, Exec. VP & Director
  • Toshiya Sasai
    Exec. of Investor Relations Group & Corp. Communications Department
  • Mr. Shinji Hidaka
    Exec. VP and Head of Marketing & Sales Division
  • Mr. Junichi Ebihara
    Exec. VP
  • Dr. Yoshiaki Ohashi (Age 63)
    SVP & Full-time Audit Supervisory Board Member
  • Mr. Tetsuya Yamaguchi
    Exec. VP and Head of Project, Lifecycle Management & Foundation Medicine Unit
  • Mr. Yoshiyuki Yano
    Exec. VP
  • Ms. Satoko Shisai
    Exec. VP & Head of Digital Transformation Unit
  • Dr. Shigehiro Yamada Ph.D. (Age 59)
    Head of Sustainability Department & Full-Time Audit & Supervisory Board Member













CHGCY Stock - Frequently Asked Questions

Should I buy or sell Chugai Pharmaceutical stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CHGCY shares.
View CHGCY analyst ratings
or view top-rated stocks.

How have CHGCY shares performed in 2023?

Chugai Pharmaceutical's stock was trading at $12.67 on January 1st, 2023. Since then, CHGCY stock has increased by 12.9% and is now trading at $14.31.
View the best growth stocks for 2023 here
.

Are investors shorting Chugai Pharmaceutical?

Chugai Pharmaceutical saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 32,100 shares, an increase of 22.5% from the August 15th total of 26,200 shares. Based on an average trading volume of 143,300 shares, the short-interest ratio is currently 0.2 days.
View Chugai Pharmaceutical's Short Interest
.

Is Chugai Pharmaceutical a good dividend stock?

Chugai Pharmaceutical (OTCMKTS:CHGCY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 1.37%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHGCY will have a dividend payout ratio of 7.94% next year. This indicates that the company will be able to sustain or increase its dividend.

What is Chugai Pharmaceutical's stock symbol?

Chugai Pharmaceutical trades on the OTCMKTS under the ticker symbol "CHGCY."

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chugai Pharmaceutical's stock price today?

One share of CHGCY stock can currently be purchased for approximately $14.31.

How much money does Chugai Pharmaceutical make?

Chugai Pharmaceutical (OTCMKTS:CHGCY) has a market capitalization of $47.08 billion and generates $9.65 billion in revenue each year. The company earns $2.88 billion in net income (profit) each year or $0.88 on an earnings per share basis.

How many employees does Chugai Pharmaceutical have?

The company employs 7,664 workers across the globe.

How can I contact Chugai Pharmaceutical?

Chugai Pharmaceutical's mailing address is 15F, Nihombashi Mitsui Tower, Chuo Ku, Tokyo To 103-8324. The official website for the company is www.chugai-pharm.co.jp. The company can be reached via phone at (133) 281-6611.

This page (OTCMKTS:CHGCY) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -